Suchergebnisse - "de Azambuja, E"

PubPharm (91)

51

Hurdles and delays in access to anti-cancer drugs in Europe

enthalten in: Ecancermedicalscience | 2014

von Ades, F. | Zardavas, D. | Senterre, C. | +5

52

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer : the LAPTEM trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von de Azambuja, E. | Zardavas, D. | Lemort, M. | +13

53

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Ades, F. | Senterre, C. | de Azambuja, E. | +4

54

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial

enthalten in: Annals of oncology | 2013

von de Azambuja, E. | Zardavas, D. | Lemort, M. | +13

55

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states

enthalten in: Annals of oncology | 2013

von Ades, F. | Senterre, C. | de Azambuja, E. | +4

56

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer : results from the NeoALTTO phase III trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Criscitiello, C. | Azim, H. | Agbor-tarh, D. | +7

CommentIn: Ann Oncol. 2014 Apr;25(4):909-10. - PMID 24608195

57

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

enthalten in: Annals of oncology | 2013

von Criscitiello, C. | Azim, H. | Agbor-tarh, D. | +7

58

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Oakman, C. | Francis, P. | Crown, J. | +18

59

Genomic grade adds prognostic value in invasive lobular carcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Metzger-Filho, O. | Michiels, S. | Bertucci, F. | +19

60

Pertuzumab : new hope for patients with HER2-positive breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Capelan, M. | Pugliano, L. | De Azambuja, E. | +5